arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

PRECIGEN, INC.

PGEN
$7.22 ▲ +0.32 (+4.64%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

PRECIGEN, INC. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $2.3B
Dividend Yield
Revenue Growth 146.7%
Op. Margin None
ROIC -96.9%
FCF / Share $-0.29
Trailing P/E
Price / Book 122.2x
FCF Yield
Debt / Equity 4.46
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.68M
↑ +146.7%
Net Income Profit after all expenses
$-250.64M
↓ -98.6%
Operating Margin Operating profit as % of sales
-314.9%
↓ -427.5%
FCF / Share Free cash flow per share
$-0.29
— -0.1%
Long-Term Debt Long-term obligations
$93.17M
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Financial Health
13
Cash Quality
34

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 57 quarters